Payment overview · 2025
General Payments
$225.97
8 reported records · 5 companies
Healthcare provider profile · identity verified
John Forrest Floyd, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SPOKANE, WA · NPI 1114913621
Verified facts
What the public records show
CMS Open Payments records show John Forrest Floyd, MD received $225.97 in general payments during 2025 across 8 reported records.
Novo Nordisk Inc accounted for 62.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $141.01 | 62.4% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $24.00 | 10.6% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $22.81 | 10.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.92 | 9.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.23 | 7.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $225.97 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $30.47 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $25.20 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $25.20 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $24.00 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $22.81 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.92 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.92 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 159 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 93 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
93 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
159 | 33 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 690 | 184 |
| Losartan Potassium | Losartan Potassium | 612 | 163 |
| Levothyroxine Sodium | Levothyroxine Sodium | 551 | 142 |
| Omeprazole | Omeprazole | 414 | 113 |
| Potassium Chloride | Potassium Chloride | 378 | 94 |
| Hydrochlorothiazide | Hydrochlorothiazide | 364 | 90 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 340 | 76 |
| Amlodipine Besylate | Amlodipine Besylate | 308 | 83 |
| Metformin Hcl | Metformin Hcl | 305 | 82 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 277 | 84 |
| Simvastatin | Simvastatin | 266 | 80 |
| Trazodone Hcl | Trazodone Hcl | 257 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 251 | 68 |
| Lisinopril | Lisinopril | 250 | 70 |
| Lorazepam | Lorazepam | 233 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 226 | 66 |
| Citalopram Hbr | Citalopram Hydrobromide | 222 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 216 | 71 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 198 | 55 |
| Zolpidem Tartrate | Zolpidem Tartrate | 194 | 44 |
| Gabapentin | Gabapentin | 192 | 59 |
| Furosemide | Furosemide | 188 | 45 |
| Eliquis | Apixaban | 159 | 33 |
| Famotidine | Famotidine | 154 | 37 |
| Alendronate Sodium | Alendronate Sodium | 151 | 38 |
| Sertraline Hcl | Sertraline Hcl | 150 | 34 |
| Allopurinol | Allopurinol | 139 | 38 |
| Donepezil Hcl | Donepezil Hcl | 139 | 38 |
| Ezetimibe | Ezetimibe | 137 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 135 | 48 |
| Glimepiride | Glimepiride | 122 | 30 |
| Montelukast Sodium | Montelukast Sodium | 120 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 116 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 107 | 30 |
| Spironolactone | Spironolactone | 102 | 24 |
| Methocarbamol | Methocarbamol | 98 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 97 | 24 |
| Tramadol Hcl | Tramadol Hcl | 97 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 93 | 14 |
| Ozempic | Semaglutide | 93 | 18 |
| Warfarin Sodium | Warfarin Sodium | 93 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 89 | 16 |
| Bupropion Hcl Sr | Bupropion Hcl | 88 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 88 | 23 |
| Amoxicillin | Amoxicillin | 82 | 60 |
| Prednisone | Prednisone | 79 | 32 |
| Jardiance | Empagliflozin | 73 | 18 |
| Xarelto | Rivaroxaban | 73 | 16 |
| Alprazolam | Alprazolam | 72 | 24 |
| Enalapril Maleate | Enalapril Maleate | 72 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 66 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 65 | 14 |
| Raloxifene Hcl | Raloxifene Hcl | 60 | 12 |
| Carvedilol | Carvedilol | 59 | 12 |
| Metformin Hcl Er | Metformin Hcl | 58 | 15 |
| Pregabalin | Pregabalin | 57 | suppressed |
| Memantine Hcl | Memantine Hcl | 55 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 51 | 18 |
| Bupropion Xl | Bupropion Hcl | 48 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 48 | 11 |
| Buspirone Hcl | Buspirone Hcl | 47 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 46 | 31 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 46 | 12 |
| Clonazepam | Clonazepam | 41 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 41 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | 11 |
| Estradiol | Estradiol | 39 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 39 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 38 | 11 |
| Propranolol Hcl | Propranolol Hcl | 38 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 37 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 37 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 37 | suppressed |
| Meloxicam | Meloxicam | 36 | 14 |
| Cartia Xt | Diltiazem Hcl | 35 | 15 |
| Clonidine Hcl | Clonidine Hcl | 35 | suppressed |
| Glipizide | Glipizide | 35 | suppressed |
| Lansoprazole | Lansoprazole | 35 | suppressed |
| Lovastatin | Lovastatin | 34 | suppressed |
| Myrbetriq | Mirabegron | 33 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 33 | suppressed |
| Atenolol | Atenolol | 32 | suppressed |
| Cephalexin | Cephalexin | 32 | 20 |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 12 |
| Terazosin Hcl | Terazosin Hcl | 31 | suppressed |
| Azithromycin | Azithromycin | 30 | 26 |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Celecoxib | Celecoxib | 29 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 29 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 29 | 11 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 28 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 28 | suppressed |
| Testosterone | Testosterone | 28 | suppressed |
| Acyclovir | Acyclovir | 27 | 15 |
| Temazepam | Temazepam | 27 | suppressed |
| Fentanyl | Fentanyl | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 22 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Methadone Hcl | Methadone Hcl | 22 | suppressed |
| Methylprednisolone | Methylprednisolone | 22 | 17 |
| Nystatin | Nystatin | 22 | suppressed |
| Torsemide | Torsemide | 22 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Cilostazol | Cilostazol | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 12 |
| Latanoprost | Latanoprost | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | 12 |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 15 |
| Colchicine | Colchicine | 16 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Dulera | Mometasone/Formoterol | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Enulose | Lactulose | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Scopolamine | Scopolamine | 13 | suppressed |
| Silodosin | Silodosin | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Epinephrine | Epinephrine | 12 | 11 |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 11 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 11 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Niacin Er | Niacin | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Triazolam | Triazolam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $225.97 · 8 records | Novo Nordisk Inc | ELIQUIS, GEMTESA, NURTEC ODT, Ozempic, REXULTI, Rybelsus, SHINGRIX, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error